Case report

Purpura in disseminated strongyloidiasis

K. Chaudhary, Russell Smith, I. M. Himelright, L. M. Baddour

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpuric lesions have been described previously in 10 patients with disseminated strongyloidiasis. We identified three additional patients in whom purpura developed as a manifestation of disseminated strongyloidiasis. Nine (69%) of the 13 patients were men, and the median age of patients was 61 years (range, 32-75 years). Six patients were from the southeastern United States. Six patients had underlying malignancy and four patients had chronic lung disease. All patients had received prior corticosteroids. The parasite was identified in 11 (92%) of 12 patients where stool or sputum examination was performed. Skin biopsies of purpuric lesions were obtained in 12 patients, in 10 (83%) of which larvae were found. Despite recommended treatment with thiabendazole in 12 of 13 patients, 11 (85%) of the patients died, and at least 6 died within 16 days of onset of purpura. Physicians, particularly those in the southeastern United States, should strongly consider the diagnosis of disseminated strongyloidiasis in patients receiving corticosteroids and in whom purpura and systemic toxicity develops.

Original languageEnglish (US)
Pages (from-to)186-191
Number of pages6
JournalAmerican Journal of the Medical Sciences
Volume308
Issue number3
DOIs
StatePublished - Jan 1 1994

Fingerprint

Strongyloidiasis
Purpura
Southeastern United States
Adrenal Cortex Hormones
Thiabendazole
Sputum

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Case report : Purpura in disseminated strongyloidiasis. / Chaudhary, K.; Smith, Russell; Himelright, I. M.; Baddour, L. M.

In: American Journal of the Medical Sciences, Vol. 308, No. 3, 01.01.1994, p. 186-191.

Research output: Contribution to journalArticle

Chaudhary, K. ; Smith, Russell ; Himelright, I. M. ; Baddour, L. M. / Case report : Purpura in disseminated strongyloidiasis. In: American Journal of the Medical Sciences. 1994 ; Vol. 308, No. 3. pp. 186-191.
@article{c186d6a68a50448aa4d4d600c6d8853c,
title = "Case report: Purpura in disseminated strongyloidiasis",
abstract = "Purpuric lesions have been described previously in 10 patients with disseminated strongyloidiasis. We identified three additional patients in whom purpura developed as a manifestation of disseminated strongyloidiasis. Nine (69{\%}) of the 13 patients were men, and the median age of patients was 61 years (range, 32-75 years). Six patients were from the southeastern United States. Six patients had underlying malignancy and four patients had chronic lung disease. All patients had received prior corticosteroids. The parasite was identified in 11 (92{\%}) of 12 patients where stool or sputum examination was performed. Skin biopsies of purpuric lesions were obtained in 12 patients, in 10 (83{\%}) of which larvae were found. Despite recommended treatment with thiabendazole in 12 of 13 patients, 11 (85{\%}) of the patients died, and at least 6 died within 16 days of onset of purpura. Physicians, particularly those in the southeastern United States, should strongly consider the diagnosis of disseminated strongyloidiasis in patients receiving corticosteroids and in whom purpura and systemic toxicity develops.",
author = "K. Chaudhary and Russell Smith and Himelright, {I. M.} and Baddour, {L. M.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1097/00000441-199409000-00014",
language = "English (US)",
volume = "308",
pages = "186--191",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Case report

T2 - Purpura in disseminated strongyloidiasis

AU - Chaudhary, K.

AU - Smith, Russell

AU - Himelright, I. M.

AU - Baddour, L. M.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Purpuric lesions have been described previously in 10 patients with disseminated strongyloidiasis. We identified three additional patients in whom purpura developed as a manifestation of disseminated strongyloidiasis. Nine (69%) of the 13 patients were men, and the median age of patients was 61 years (range, 32-75 years). Six patients were from the southeastern United States. Six patients had underlying malignancy and four patients had chronic lung disease. All patients had received prior corticosteroids. The parasite was identified in 11 (92%) of 12 patients where stool or sputum examination was performed. Skin biopsies of purpuric lesions were obtained in 12 patients, in 10 (83%) of which larvae were found. Despite recommended treatment with thiabendazole in 12 of 13 patients, 11 (85%) of the patients died, and at least 6 died within 16 days of onset of purpura. Physicians, particularly those in the southeastern United States, should strongly consider the diagnosis of disseminated strongyloidiasis in patients receiving corticosteroids and in whom purpura and systemic toxicity develops.

AB - Purpuric lesions have been described previously in 10 patients with disseminated strongyloidiasis. We identified three additional patients in whom purpura developed as a manifestation of disseminated strongyloidiasis. Nine (69%) of the 13 patients were men, and the median age of patients was 61 years (range, 32-75 years). Six patients were from the southeastern United States. Six patients had underlying malignancy and four patients had chronic lung disease. All patients had received prior corticosteroids. The parasite was identified in 11 (92%) of 12 patients where stool or sputum examination was performed. Skin biopsies of purpuric lesions were obtained in 12 patients, in 10 (83%) of which larvae were found. Despite recommended treatment with thiabendazole in 12 of 13 patients, 11 (85%) of the patients died, and at least 6 died within 16 days of onset of purpura. Physicians, particularly those in the southeastern United States, should strongly consider the diagnosis of disseminated strongyloidiasis in patients receiving corticosteroids and in whom purpura and systemic toxicity develops.

UR - http://www.scopus.com/inward/record.url?scp=0027967933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027967933&partnerID=8YFLogxK

U2 - 10.1097/00000441-199409000-00014

DO - 10.1097/00000441-199409000-00014

M3 - Article

VL - 308

SP - 186

EP - 191

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 3

ER -